2-(2-(piperidin-1-yl)ethoxy)ethan-1-amine | 933716-53-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(2-(piperidin-1-yl)ethoxy)ethan-1-amine
• 英文别名: 2-(2-(Piperidin-1-yl)ethoxy)ethanamine；2-(2-piperidin-1-ylethoxy)ethanamine
• CAS: 933716-53-1
• 化学式: C₉H₂₀N₂O
• 分子量: 172.271
• InChiKey: WRDVFCGTKXQHPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[1-carboxymethyl-1H-quinolin-4-ylidenemethyl]-3-methylbezothiazolium bromide 、 2-(2-(piperidin-1-yl)ethoxy)ethan-1-amine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 以18.3%的产率得到2-[4-[(Z)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]quinolin-1-ium-1-yl]-N-[2-(2-piperidin-1-ylethoxy)ethyl]acetamide;bromide
  参考文献：
  名称：

  Thiazole orange – Spermine conjugate: A potent human telomerase inhibitor comparable to BRACO-19

  摘要：

  In this report, we synthesized a series of TO conjugates containing different amino side chains and investigated their binding to telomeric G-quadruplex DNA (G4) using several biophysical methods including fluorometric titration and thermal denaturation monitored by fluorescence and circular dichroism. The composition of side chains strongly affects the binding of these molecules to G-quadruplex DNA. Incorporation of amino side chains increases the binding affinity of TO toward G4 but has a minimal effect on its selectivity for G4 over duplex DNA. The plausible binding modes are a synergistic effect of end-stacking and groove interactions as indicated by docking studies. Inhibition of human telomerase activity by TO derivatives was determined in vitro by the TRAP assay. Several derivatives can selectively inhibit the activity of telomerase over DNA polymerase at low concentrations. More significantly, TO-spermine conjugate (16) exhibits a remarkable effect on telomerase inhibition in the submicromolar range, which is comparable to the inhibition effect of a well-known G4 ligand, BRACO-19. Our results here provide guidance of utilizing TO derivatives as a viable scaffold to design novel G4 ligands, G4 probes, and potent telomerase inhibitors. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.04.041
• 作为产物：
  描述：

  在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 0.5h， 生成 2-(2-(piperidin-1-yl)ethoxy)ethan-1-amine
  参考文献：
  名称：

  Thiazole orange – Spermine conjugate: A potent human telomerase inhibitor comparable to BRACO-19

  摘要：

  In this report, we synthesized a series of TO conjugates containing different amino side chains and investigated their binding to telomeric G-quadruplex DNA (G4) using several biophysical methods including fluorometric titration and thermal denaturation monitored by fluorescence and circular dichroism. The composition of side chains strongly affects the binding of these molecules to G-quadruplex DNA. Incorporation of amino side chains increases the binding affinity of TO toward G4 but has a minimal effect on its selectivity for G4 over duplex DNA. The plausible binding modes are a synergistic effect of end-stacking and groove interactions as indicated by docking studies. Inhibition of human telomerase activity by TO derivatives was determined in vitro by the TRAP assay. Several derivatives can selectively inhibit the activity of telomerase over DNA polymerase at low concentrations. More significantly, TO-spermine conjugate (16) exhibits a remarkable effect on telomerase inhibition in the submicromolar range, which is comparable to the inhibition effect of a well-known G4 ligand, BRACO-19. Our results here provide guidance of utilizing TO derivatives as a viable scaffold to design novel G4 ligands, G4 probes, and potent telomerase inhibitors. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.04.041

文献信息

• [EN] NOVEL IMIDAZOPYRAZINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'IMIDAZOPYRAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020126954A1

  公开（公告）日：2020-06-25

  The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

  该发明提供了具有通式（I）的新型咪唑吡嗪衍生物，其中A和R1至R11如本文所述（I），以及其药学上可接受的盐。还提供了包括这些化合物的药物组合物、制造这些化合物的方法以及将这些化合物用作药物的方法，特别是将这些化合物用作抗生素治疗或预防细菌感染和相关疾病的方法。
• 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
  申请人：Luk Kin-Chun

  公开号：US20050256154A1

  公开（公告）日：2005-11-17

  Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon, lung and prostate. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer using these compounds.

  本文披露了一种新颖的4-氨基噻吩[3,2-c]吡啶-7-羧酸酰胺，以及它们的药用盐和酯，这些化合物是KDR和/或FGFR激酶的选择性抑制剂。这些化合物及其药用盐是抗增殖剂，可用于治疗或控制实体肿瘤，特别是乳腺、结肠、肺和前列腺的实体癌性肿瘤。还披露了含有这些化合物的药物组合物和使用这些化合物治疗癌症的方法。
• Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening
  作者：Jeremy S. Disch、Jennifer M. Duffy、Esther C. Y. Lee、Diana Gikunju、Betty Chan、Benjamin Levin、Michael I. Monteiro、Sarah A. Talcott、Anthony C. Lau、Fei Zhou、Anton Kozhushnyan、Neil E. Westlund、Patrick B. Mullins、Yan Yu、Moritz von Rechenberg、Junyi Zhang、Yelena A. Arnautova、Yanbin Liu、Ying Zhang、Andrew J. McRiner、Anthony D. Keefe、Anna Kohlmann、Matthew A. Clark、John W. Cuozzo、Christelle Huguet、Shilpi Arora

  DOI：10.1021/acs.jmedchem.1c00127

  日期：2021.4.22

  breast cancer. Information from DNA-encoded chemical library (DECL) screening provides a method to identify novel PROTAC binding features as the linker positioning, and binding elements are determined directly from the screen. After screening ∼120 billion DNA-encoded molecules with ERα WT and 3 gain-of-function (GOF) mutants, with and without estradiol to identify features that enrich ERα competitively

  预期ERα的双特异性降解物（PROTAC）优于目前用于治疗ER +乳腺癌的ERα信号传导抑制剂（芳香酶抑制剂/ SERM / SERD）。来自DNA编码化学文库（DECL）筛选的信息提供了一种方法，可在接头定位时识别新颖的PROTAC结合特征，并直接从筛选中确定结合元件。在筛选出约1200亿个带有ERαWT和3个功能获得（GOF）突变体的DNA编码分子后，无论是否存在雌二醇，以鉴定出竞争性富集ERα的特征，脱DNA合成的小分子样本7表现出纳摩尔ERα结合，拮抗作用和退化。在炔烃E3连接酶接合体面板和7的叠氮化物变体上单击化学合成迅速产生的ERα双特异性纳摩尔降解物，在小鼠乳腺癌异种移植模型中，PROTAC 18和21抑制ER + MCF7肿瘤的生长。这项研究验证了这种通过最小的优化从DECL筛选中鉴定新型双特异性降解物引物的方法。
• Cytotoxicity and DNA-binding property of water-soluble naphthalene diimide derivatives bearing 2-oligoethoxy ethanamine side chain end-labeled with tertiary amino groups
  作者：Haiying Wei、Mengjiao Lv、Xiaoxu Duan、Shuai Li、Yuchao Yao、Kerang Wang、Pingzhu Zhang、Xiaoliu Li、Hua Chen

  DOI：10.1007/s00044-013-0823-x

  日期：2014.5

  anti-proliferative activity. Their DNA-binding properties were also studied using UV–Vis spectroscopy, fluorescence spectroscopy, and circular dichroism. The results showed that such tri-substituted NDI as DNA intercalators exhibited strong π–π stack binding capability and high binding affinities towards calf thymus (Ct) DNA and G-quadruplex (G4) DNA. The order of the binding constants is Ct-DNA > G4 DNA, which

  摘要设计并合成了一系列新型的带有2-氨基乙氧基乙胺侧链末端标记有叔氨基的水溶性三取代萘二酰亚胺（NDI）衍生物。新型萘二酰亚胺对癌细胞系（K562，A549和HeLa）的细胞毒性表明，这些化合物具有出色的抗癌活性，并且发现侧链较短（具有一个氧化乙烯）有利于观察到的抗癌性。增殖活动。还使用紫外可见光谱，荧光光谱和圆二色性研究了它们的DNA结合特性。结果表明，这种三取代NDI作为DNA嵌入剂表现出强大的π–π堆栈结合能力以及对小胸腺（Ct）DNA和G-四链体（G4）DNA的高结合亲和力。 图形概要设计并合成了一系列带有2-氨基乙氧基乙胺侧链末端标记有叔氨基的新型水溶性三取代NDI衍生物。这些化合物具有优异的抗癌活性，并且短链的侧链（具有一个氧化乙烯）将有利于其抗增殖活性。
• NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1917015A1

  公开（公告）日：2008-05-07